Characterization of patients in the European Forsteo Observational Study (EFOS): Postmenopausal women entering teriparatide treatment in a community setting

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 377-384

  Rajzbaum, Gerald ^a   Jakob, Franz ^b   Karras, Dimitrios ^c   Ljunggren, Östen ^d   Lems, Willem F ^e   Langdahl, Bente L ^f   Fahrleitner Pammer, Astrid ^g   Walsh, J Bernard ^h   Gibson, Anthony ⁱ   Tynan, Aodán J ⁱ   Marin, Fernando ⁱ  

^a SAINT JOSEPH HOSPITAL   (France)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Veterans Administration Hospital NIMTS   (Greece)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e SLOTERVAART HOSPITAL   (Netherlands)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h TRINITY COLLEGE DUBLIN   (Ireland)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Back pain; EQ 5D; Fracture; Menopause; Osteoporosis; Quality of life; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AGE DISTRIBUTION; AGED; ANXIETY; ARTICLE; BACKACHE; BONE DENSITY; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; FEMALE; FRACTURE; HEALTH STATUS; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT OUTCOME; VERTEBRA MALFORMATION; VISUAL ANALOG SCALE;

AGED; BACK PAIN; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EUROPE; FEMALE; FRACTURES, BONE; HEALTH SURVEYS; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS; PAIN MEASUREMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RESIDENCE CHARACTERISTICS; SICKNESS IMPACT PROFILE; TERIPARATIDE;

EID: 39749147712     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X261087     Document Type: Article

References (22)

1. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization, 1994. Report no 843
2. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized, controlled trial. JAMA 1999;282:1344-52
4. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
5. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
6. Lundkvist J, Johnell O, Cooper C, Sykes D. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 2006;17:201-11
7. Eli Lilly and Company. FORSTEO (teriparatide [rDNA origin] injection). Product label, 2006. Available from http://www.emea.eu.int/humandocs/Humans/ EPAR/forsteo/forsteo.htm [Last accessed 26 Mar 2007]
8. The EuroQol Group. EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
9. Szende A, Williams A, editors. Measuring self-reported population health: an international perspective based on EQ-5D. ISBN 963 94 56 470. SpringMed Publishing Ltd, 2004
10. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos Int 2005;16:447-55
11. Brenneman SK, Barrett-Connor E, Sajjan S, et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809-16
12. Oleksik AM, Ewing S, Shen W, et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861-70
13. Hallberg I, Rosenqvist AM, Kartous L, et al. Health-related quality of life after osteoporotic fractures. Osteoporos Int 2004;15:834-41
14. Adachi JD, Ioannidis G, Olszynski WP, et al. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 2002;3:11
15. de Oliveira PP, Klumb EM, Marinheiro LP. Prevalence of fracture risk estimated by quantitative ultrasound of the calcaneus in a population of postmenopausal women. Cad Saude Publica 2007;23:381-90
16. Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic Publishers, 2003
17. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82
18. de Vries M, Ouwendijk R, Kessels AG, et al. Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. J Vasc Surg 2005;41:261-8
19. Wasserfallen J-B, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:1594-9
20. van Schoor NM, Smit JH, Twisk JWR, Lips P. Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos Int 2005;16:749-56
21. Silverman SL, Piziak VK, Chen P, et al. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005;32:2405-9
22. Cockerill W, Lunt M, Silman AJ, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004;15:113-9